<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30036867</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>07</Month>            <Day>31</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1423-0232</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>94 Suppl 1</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Oncology</Title>                <ISOAbbreviation>Oncology</ISOAbbreviation>            </Journal>            <ArticleTitle>Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.</ArticleTitle>            <Pagination>                <MedlinePgn>10-15</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000489063</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced breast cancer (BC) in a real-life setting.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective monocentric study included patients with HER-2-negative metastatic BC, pretreated with anthracyclines and taxanes, who were referred to the Oncology Department of Spedali Civili of Brescia from May 2012 to April 2017. Patients received the same dose of eribulin as that used in the EMBRACE trial: 1.4 mg/m2 on days 1 and 8 every 21 days.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In a total of 53 patients, 32% obtained a partial response, 11% a stable disease, and 43% a clinical benefit (CB). After a median follow-up of 36 months, median progression-free survival (PFS) was 4.7 months and median overall survival (OS) 13.53 months. Median PFS was significantly longer in patients who reported a CB compared to those with no CB, while survival outcomes (PFS and OS) were better in patients who received &gt; 6 cycles of eribulin. Eribulin showed a good tolerability profile with acceptable toxicities, similar to those reported in EMBRACE.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our experience in a real-world setting confirms the activity, efficacy, and good tolerability profile of eribulin in heavily pretreated BC patients.</AbstractText>                <CopyrightInformation>Â© 2018 S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Pedersini</LastName>                    <ForeName>Rebecca</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Unit-Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vassalli</LastName>                    <ForeName>Lucia</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Unit-Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Claps</LastName>                    <ForeName>Melanie</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tulla</LastName>                    <ForeName>Antonella</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rodella</LastName>                    <ForeName>Filippo</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Grisanti</LastName>                    <ForeName>Salvatore</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Amoroso</LastName>                    <ForeName>Vito</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roca</LastName>                    <ForeName>Elisa</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Simoncini</LastName>                    <ForeName>Edda Lucia</ForeName>                    <Initials>EL</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Unit, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berruti</LastName>                    <ForeName>Alfredo</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Oncology</MedlineTA>            <NlmUniqueID>0135054</NlmUniqueID>            <ISSNLinking>0030-2414</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018943">Anthracyclines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D005663">Furans</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007659">Ketones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>LR24G6354G</RegistryNumber>                <NameOfSubstance UI="C490954">eribulin</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Invest. 2009 Jan;27(1):81-5</RefSource>                <PMID Version="1">19191099</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drugs Context. 2017 Nov 08;6:212506</RefSource>                <PMID Version="1">29167692</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Chemotherapy. 2017;62(1):71-79</RefSource>                <PMID Version="1">27648841</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2014 Mar 20;5(5):320-7</RefSource>                <PMID Version="1">24723974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2017 Apr;13(11s):5-10</RefSource>                <PMID Version="1">28481186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ther Adv Med Oncol. 2013 Nov;5(6):334-50</RefSource>                <PMID Version="1">24179488</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Oncol. 2015 Apr;54(4):522-9</RefSource>                <PMID Version="1">25383448</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2015;11(3):431-8</RefSource>                <PMID Version="1">25675124</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Mar 12;377(9769):914-23</RefSource>                <PMID Version="1">21376385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2011 Jan 15;71(2):496-505</RefSource>                <PMID Version="1">21127197</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2005 Jul;4(7):1086-95</RefSource>                <PMID Version="1">16020666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2017 Apr;13(11s):25-33</RefSource>                <PMID Version="1">28481183</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2005 Apr;6(1):55-60</RefSource>                <PMID Version="1">15899073</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer. 2017 Mar;24(2):171-179</RefSource>                <PMID Version="1">27491426</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ther Adv Med Oncol. 2016 May;8(3):209-29</RefSource>                <PMID Version="1">27239239</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2017 Apr;13(11s):11-23</RefSource>                <PMID Version="1">28481185</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2014 Dec;148(3):553-61</RefSource>                <PMID Version="1">25381136</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2011 Apr;11(2):73-81</RefSource>                <PMID Version="1">21569993</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2012 Jun;23(6):1441-8</RefSource>                <PMID Version="1">21989327</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Springerplus. 2015 Oct 19;4:625</RefSource>                <PMID Version="1">26543760</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29</RefSource>                <PMID Version="1">25559415</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Control. 2015 Apr;22(2):211-9</RefSource>                <PMID Version="1">26068767</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Jun 20;27(18):2954-61</RefSource>                <PMID Version="1">19349550</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2011 Dec;20(6):574-8</RefSource>                <PMID Version="1">21852136</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochemistry. 2010 Feb 16;49(6):1331-7</RefSource>                <PMID Version="1">20030375</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Feb 20;33(6):594-601</RefSource>                <PMID Version="1">25605862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2008 Jan;107(2):275-9</RefSource>                <PMID Version="1">17380382</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Sep 1;28(25):3922-8</RefSource>                <PMID Version="1">20679609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2010 Nov 9;103(10):1518-23</RefSource>                <PMID Version="1">20978502</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018943" MajorTopicYN="N">Anthracyclines</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Eribulin</Keyword>            <Keyword MajorTopicYN="N">Metastatic breast cancer</Keyword>            <Keyword MajorTopicYN="N">Overall survival</Keyword>            <Keyword MajorTopicYN="N">Progression-free survival</Keyword>            <Keyword MajorTopicYN="N">Real-world practice</Keyword>            <Keyword MajorTopicYN="N">Safety</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30036867</ArticleId>            <ArticleId IdType="pii">000489063</ArticleId>            <ArticleId IdType="doi">10.1159/000489063</ArticleId>            <ArticleId IdType="pmc">PMC6193751</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>